Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

Sonali M. Smith, James Godfrey, Kwang Woo Ahn, Alyssa DiGilio, Sairah Ahmed, Vaibhav Agrawal, Veronika Bachanova, Ulrike Bacher, Asad Bashey, Javier Bolaños-Meade, Mitchell Cairo, Andy Chen, Saurabh Chhabra, Edward Copelan, Parastoo B. Dahi, Mahmoud Aljurf, Umar Farooq, Siddhartha Ganguly, Mark Hertzberg, Leona HolmbergDavid Inwards, Abraham S. Kanate, Reem Karmali, Vaishalee P. Kenkre, Mohamed A. Kharfan-Dabaja, Andreas Klein, Hillard M. Lazarus, Matthew Mei, Alberto Mussetti, Taiga Nishihori, Praveen Ramakrishnan Geethakumari, Ayman Saad, Bipin N. Savani, Harry C. Schouten, Nirav Shah, Alvaro Urbano-Ispizua, Ravi Vij, Julie Vose, Anna Sureda, Mehdi Hamadani

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND: Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high-risk group of patients with an expected 5-year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated. METHODS: This study compared autologous hematopoietic stem cell transplantation (auto-HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo-HCT) as the first transplantation approach for patients with ETF FL (age ≥ 18 years) undergoing auto-HCT or allo-HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression-free survival, relapse, and nonrelapse mortality (NRM). RESULTS: Four hundred forty FL patients had ETF (auto-HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow-up of 69 to 73 months, the adjusted probability of 5-year OS was significantly higher after auto-HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P =.0008). The 5-year adjusted probability of NRM was significantly lower for auto-HCT (5%) versus MSD (17%) or MUD HCT (33%; P <.0001). The 5-year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto-HCT (58%; P <.0001). CONCLUSIONS: Patients with high-risk FL, as defined by ETF, undergoing auto-HCT for FL have low NRM and a promising 5-year OS rate (70%). MSD HCT has lower relapse rates than auto-HCT but similar OS. Cancer 2018;124:2541-51.

Original languageEnglish (US)
Pages (from-to)2541-2551
Number of pages11
JournalCancer
Volume124
Issue number12
DOIs
StatePublished - Jun 15 2018

Fingerprint

Follicular Lymphoma
Autologous Transplantation
Hematopoietic Stem Cell Transplantation
Homologous Transplantation
Treatment Failure
Unrelated Donors
Siblings
Tissue Donors
Recurrence
Survival
Cell Transplantation
Mortality
Survival Rate
Transplantation

Keywords

  • allogeneic transplantation
  • autologous transplantation
  • chemoimmunotherapy
  • early treatment failure
  • follicular lymphoma
  • rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Smith, S. M., Godfrey, J., Ahn, K. W., DiGilio, A., Ahmed, S., Agrawal, V., ... Hamadani, M. (2018). Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer, 124(12), 2541-2551. https://doi.org/10.1002/cncr.31374

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. / Smith, Sonali M.; Godfrey, James; Ahn, Kwang Woo; DiGilio, Alyssa; Ahmed, Sairah; Agrawal, Vaibhav; Bachanova, Veronika; Bacher, Ulrike; Bashey, Asad; Bolaños-Meade, Javier; Cairo, Mitchell; Chen, Andy; Chhabra, Saurabh; Copelan, Edward; Dahi, Parastoo B.; Aljurf, Mahmoud; Farooq, Umar; Ganguly, Siddhartha; Hertzberg, Mark; Holmberg, Leona; Inwards, David; Kanate, Abraham S.; Karmali, Reem; Kenkre, Vaishalee P.; Kharfan-Dabaja, Mohamed A.; Klein, Andreas; Lazarus, Hillard M.; Mei, Matthew; Mussetti, Alberto; Nishihori, Taiga; Ramakrishnan Geethakumari, Praveen; Saad, Ayman; Savani, Bipin N.; Schouten, Harry C.; Shah, Nirav; Urbano-Ispizua, Alvaro; Vij, Ravi; Vose, Julie; Sureda, Anna; Hamadani, Mehdi.

In: Cancer, Vol. 124, No. 12, 15.06.2018, p. 2541-2551.

Research output: Contribution to journalArticle

Smith, SM, Godfrey, J, Ahn, KW, DiGilio, A, Ahmed, S, Agrawal, V, Bachanova, V, Bacher, U, Bashey, A, Bolaños-Meade, J, Cairo, M, Chen, A, Chhabra, S, Copelan, E, Dahi, PB, Aljurf, M, Farooq, U, Ganguly, S, Hertzberg, M, Holmberg, L, Inwards, D, Kanate, AS, Karmali, R, Kenkre, VP, Kharfan-Dabaja, MA, Klein, A, Lazarus, HM, Mei, M, Mussetti, A, Nishihori, T, Ramakrishnan Geethakumari, P, Saad, A, Savani, BN, Schouten, HC, Shah, N, Urbano-Ispizua, A, Vij, R, Vose, J, Sureda, A & Hamadani, M 2018, 'Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure', Cancer, vol. 124, no. 12, pp. 2541-2551. https://doi.org/10.1002/cncr.31374
Smith, Sonali M. ; Godfrey, James ; Ahn, Kwang Woo ; DiGilio, Alyssa ; Ahmed, Sairah ; Agrawal, Vaibhav ; Bachanova, Veronika ; Bacher, Ulrike ; Bashey, Asad ; Bolaños-Meade, Javier ; Cairo, Mitchell ; Chen, Andy ; Chhabra, Saurabh ; Copelan, Edward ; Dahi, Parastoo B. ; Aljurf, Mahmoud ; Farooq, Umar ; Ganguly, Siddhartha ; Hertzberg, Mark ; Holmberg, Leona ; Inwards, David ; Kanate, Abraham S. ; Karmali, Reem ; Kenkre, Vaishalee P. ; Kharfan-Dabaja, Mohamed A. ; Klein, Andreas ; Lazarus, Hillard M. ; Mei, Matthew ; Mussetti, Alberto ; Nishihori, Taiga ; Ramakrishnan Geethakumari, Praveen ; Saad, Ayman ; Savani, Bipin N. ; Schouten, Harry C. ; Shah, Nirav ; Urbano-Ispizua, Alvaro ; Vij, Ravi ; Vose, Julie ; Sureda, Anna ; Hamadani, Mehdi. / Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. In: Cancer. 2018 ; Vol. 124, No. 12. pp. 2541-2551.
@article{066b058554ef434c974d5d80e3352d2b,
title = "Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure",
abstract = "BACKGROUND: Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high-risk group of patients with an expected 5-year overall survival (OS) rate of approximately 50{\%}. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated. METHODS: This study compared autologous hematopoietic stem cell transplantation (auto-HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo-HCT) as the first transplantation approach for patients with ETF FL (age ≥ 18 years) undergoing auto-HCT or allo-HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression-free survival, relapse, and nonrelapse mortality (NRM). RESULTS: Four hundred forty FL patients had ETF (auto-HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow-up of 69 to 73 months, the adjusted probability of 5-year OS was significantly higher after auto-HCT (70{\%}) or MSD HCT (73{\%}) versus MUD HCT (49{\%}; P =.0008). The 5-year adjusted probability of NRM was significantly lower for auto-HCT (5{\%}) versus MSD (17{\%}) or MUD HCT (33{\%}; P <.0001). The 5-year adjusted probability of disease relapse was lower with MSD (31{\%}) or MUD HCT (23{\%}) versus auto-HCT (58{\%}; P <.0001). CONCLUSIONS: Patients with high-risk FL, as defined by ETF, undergoing auto-HCT for FL have low NRM and a promising 5-year OS rate (70{\%}). MSD HCT has lower relapse rates than auto-HCT but similar OS. Cancer 2018;124:2541-51.",
keywords = "allogeneic transplantation, autologous transplantation, chemoimmunotherapy, early treatment failure, follicular lymphoma, rituximab",
author = "Smith, {Sonali M.} and James Godfrey and Ahn, {Kwang Woo} and Alyssa DiGilio and Sairah Ahmed and Vaibhav Agrawal and Veronika Bachanova and Ulrike Bacher and Asad Bashey and Javier Bola{\~n}os-Meade and Mitchell Cairo and Andy Chen and Saurabh Chhabra and Edward Copelan and Dahi, {Parastoo B.} and Mahmoud Aljurf and Umar Farooq and Siddhartha Ganguly and Mark Hertzberg and Leona Holmberg and David Inwards and Kanate, {Abraham S.} and Reem Karmali and Kenkre, {Vaishalee P.} and Kharfan-Dabaja, {Mohamed A.} and Andreas Klein and Lazarus, {Hillard M.} and Matthew Mei and Alberto Mussetti and Taiga Nishihori and {Ramakrishnan Geethakumari}, Praveen and Ayman Saad and Savani, {Bipin N.} and Schouten, {Harry C.} and Nirav Shah and Alvaro Urbano-Ispizua and Ravi Vij and Julie Vose and Anna Sureda and Mehdi Hamadani",
year = "2018",
month = "6",
day = "15",
doi = "10.1002/cncr.31374",
language = "English (US)",
volume = "124",
pages = "2541--2551",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

AU - Smith, Sonali M.

AU - Godfrey, James

AU - Ahn, Kwang Woo

AU - DiGilio, Alyssa

AU - Ahmed, Sairah

AU - Agrawal, Vaibhav

AU - Bachanova, Veronika

AU - Bacher, Ulrike

AU - Bashey, Asad

AU - Bolaños-Meade, Javier

AU - Cairo, Mitchell

AU - Chen, Andy

AU - Chhabra, Saurabh

AU - Copelan, Edward

AU - Dahi, Parastoo B.

AU - Aljurf, Mahmoud

AU - Farooq, Umar

AU - Ganguly, Siddhartha

AU - Hertzberg, Mark

AU - Holmberg, Leona

AU - Inwards, David

AU - Kanate, Abraham S.

AU - Karmali, Reem

AU - Kenkre, Vaishalee P.

AU - Kharfan-Dabaja, Mohamed A.

AU - Klein, Andreas

AU - Lazarus, Hillard M.

AU - Mei, Matthew

AU - Mussetti, Alberto

AU - Nishihori, Taiga

AU - Ramakrishnan Geethakumari, Praveen

AU - Saad, Ayman

AU - Savani, Bipin N.

AU - Schouten, Harry C.

AU - Shah, Nirav

AU - Urbano-Ispizua, Alvaro

AU - Vij, Ravi

AU - Vose, Julie

AU - Sureda, Anna

AU - Hamadani, Mehdi

PY - 2018/6/15

Y1 - 2018/6/15

N2 - BACKGROUND: Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high-risk group of patients with an expected 5-year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated. METHODS: This study compared autologous hematopoietic stem cell transplantation (auto-HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo-HCT) as the first transplantation approach for patients with ETF FL (age ≥ 18 years) undergoing auto-HCT or allo-HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression-free survival, relapse, and nonrelapse mortality (NRM). RESULTS: Four hundred forty FL patients had ETF (auto-HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow-up of 69 to 73 months, the adjusted probability of 5-year OS was significantly higher after auto-HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P =.0008). The 5-year adjusted probability of NRM was significantly lower for auto-HCT (5%) versus MSD (17%) or MUD HCT (33%; P <.0001). The 5-year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto-HCT (58%; P <.0001). CONCLUSIONS: Patients with high-risk FL, as defined by ETF, undergoing auto-HCT for FL have low NRM and a promising 5-year OS rate (70%). MSD HCT has lower relapse rates than auto-HCT but similar OS. Cancer 2018;124:2541-51.

AB - BACKGROUND: Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high-risk group of patients with an expected 5-year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated. METHODS: This study compared autologous hematopoietic stem cell transplantation (auto-HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo-HCT) as the first transplantation approach for patients with ETF FL (age ≥ 18 years) undergoing auto-HCT or allo-HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression-free survival, relapse, and nonrelapse mortality (NRM). RESULTS: Four hundred forty FL patients had ETF (auto-HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow-up of 69 to 73 months, the adjusted probability of 5-year OS was significantly higher after auto-HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P =.0008). The 5-year adjusted probability of NRM was significantly lower for auto-HCT (5%) versus MSD (17%) or MUD HCT (33%; P <.0001). The 5-year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto-HCT (58%; P <.0001). CONCLUSIONS: Patients with high-risk FL, as defined by ETF, undergoing auto-HCT for FL have low NRM and a promising 5-year OS rate (70%). MSD HCT has lower relapse rates than auto-HCT but similar OS. Cancer 2018;124:2541-51.

KW - allogeneic transplantation

KW - autologous transplantation

KW - chemoimmunotherapy

KW - early treatment failure

KW - follicular lymphoma

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=85045242474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045242474&partnerID=8YFLogxK

U2 - 10.1002/cncr.31374

DO - 10.1002/cncr.31374

M3 - Article

C2 - 29645093

AN - SCOPUS:85045242474

VL - 124

SP - 2541

EP - 2551

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -